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Heart failure is the major cause of
death in the western world. Despite
the development and use of standard
evidence-based therapeutic strategies for
heart failure like inhibition of the activ-
ity of the β-adrenergic signaling and
renin-angiotensin-aldosterone system,
the prevalence of heart failure is still
increasing, while morbidity and mortal-
ity have not been satisfactorily improved
(Hofmann and Frantz, 2013). Growing
evidence has indicated that the rising
incidence of heart failure is substantially
associated with age. In the United States, a
high proportion of the estimated 5 million
heart failure patients are older people, and
a vast majority of heart failure-related hos-
pitalization and death occurred in patients
over 65 years old (Go et al., 2014). With
the tendency of global aging, it is necessary
to go deeper in exploring the aging-related
heart failure.
Cardiac aging is characterized by a
series of complex events of ventricle and
valvular changes involving left ventric-
ular hypertrophy, diastolic dysfunction,
increased risk of atrial fibrillation, valvular
degeneration and fibrosis, and decreased
maximal exercise capacity. These changes
make the aged heart more susceptible to
stress, leading to a high prevalence of
cardiovascular diseases and heart failure
(Correia et al., 2002; Dai et al., 2012a).
The mechanisms of progression to heart
failure in the aged heart have been pre-
viously described. The oxidative stress
and mitochondrial damage are responsible
for triggering the increased cardiomyocyte
death including necrosis, apoptosis and
autophagy, accompanied by hypertrophy
of remaining cells and impaired structure
of extracellular matrix (ECM), thus lead-
ing to ventricular remodeling and reduced
cardiac contractility (Nadal-Ginard et al.,
2003; Sarkar et al., 2004; Lindsey et al.,
2006; Dai et al., 2012b; Venkataraman
et al., 2013). Meanwhile, cardiac hyper-
trophy leads to a mismatch in oxygen
supply and demand, which contributes to
endothelial dysfunction and angiogenesis
(Shiojima et al., 2005; Izumiya et al., 2006;
Heineke et al., 2007). In response to these
chronic stress, the aged heart undergoes a
complex pathophysiological changes and
finally progresses to symptomatic heart
failure (Foo et al., 2005; Dai et al., 2012a).
MicroRNAs (miRNAs,miRs) are anovel
class of small non-coding RNAs with
approximately 20-24 length of base, which
function as endogenous suppressors of
gene expression through mRNA degrada-
tion and/or translational inhibitionmainly
by binding to 3′-untranslated region (3′-
UTR) of target mRNAs (Lim et al., 2005;
VanRooij,2011).Nowadaysover2000miR-
NAshavebeen identified inhumangenome
and each miRNA can modulate numerous
target genes and build complex signal-
ing networks (Kim and Nam, 2006; Liang,
2009). As a center player of gene regulation,
many essential biological processes are reg-
ulated bymiRNAs, including proliferation,
apoptosis, necrosis, autophagy, differenti-
ation, and stress responses (Bartel, 2004).
Due to these multiple roles, miRNAs
are critically involved in the develop-
ment of multifarious heart diseases, such
as heart hypertrophy, arrhythmia, acute
myocardial infarction, and heart failure
(Latronico and Condorelli, 2009; Xiao
et al., 2012, 2014; Fu et al., 2013; Vickers
et al., 2014). Several microarray studies
have revealed expression profiles of spe-
cific miRNAs that are aberrantly expressed
in heart failure. MiR-1, -29, -30, -133,
and -150 were found to be downregu-
lated in heart failure, whereas miR-21, -23,
-27, -125, -132, -146, -195, -199, -214,
-223, and 342 were upregulated (Van Rooij
et al., 2006; Cheng et al., 2007; Ikeda et al.,
2007; Sayed et al., 2007; Tatsuguchi et al.,
2007; Thum et al., 2007; Sucharov et al.,
2008; Matkovich et al., 2009; Naga Prasad
et al., 2009). In addition, several circulat-
ing miRNAs including miR-423-5P have
been considered as putative biomarkers for
heart failure (Tijsen et al., 2010). Some dis-
tinguished reviews have summarized it in
detail (Elzenaar et al., 2013; Kumarswamy
and Thum, 2013; De Rosa et al., 2014;
Harada et al., 2014).
As we know, cardiac aging is among
the predominant risk factors for the devel-
opment of heart failure (Correia et al.,
2002; Dai et al., 2012a). Recent advances
suggest that miRNAs may also play a
role in the regulation of gene expression
in cardiovascular aging processes (Zhang
et al., 2012; Olivieri et al., 2013; Menghini
et al., 2014). It has been previously demon-
strated that 65 miRNAs were differen-
tially expressed in the old versus young
mouse adult hearts, approximately half of
which belong to 11 miRNA clusters, indi-
cating that these clusters contribute to
the complex regulation of gene expression
during heart aging (Zhang et al., 2012).
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In addition, miR-22 was shown to be
involved in aging-related cardiac fibrosis,
whose overexpression contributed to cel-
lular senescence and migration of cardiac
fibroblasts (Jazbutyte et al., 2013). More
recently, it was demonstrated that aging-
induced expression of miR-34a and inhibi-
tion of its target PNUTs lead to increased
cardiomyocyte death and reduced car-
diac contractility function, by inducing
telomere shortening and DNA damage
responses (Boon et al., 2013).
However, the role of miRNAs in aging-
related heart failure is far from elucidated.
A previous study showed that themembers
of miR-17-92 cluster, including miR-18a,
-19a, and -19b, were all downregulated in
failure-prone heart of aged mice as well as
in cardiac biopsies of idiopathic cardiomy-
opathy patients at old age with severely
impaired cardiac function (ejection frac-
tion, EF<30%), accompanied by increased
expression of the ECM proteins connec-
tive tissue growth factor (CTGF) and
thrombospondin-1 (TSP-1). Furthermore,
the in vitro studies showed that these
expression changes were specific in aged
cardiomyocytes but not in cardiac fibrob-
lasts, and the inhibition of miR-18/19
in cardiomyocytes contributed to colla-
gen synthesis (Collagen 1A1 and 1A3) via
the regulation of pro-fibrotic CTGF and
TSP-1. Although the mechanisms under-
lying these regulations are still unknown, it
provides a close relationship betweenmiR-
18/19 and aging-induced cardiac remod-
eling and heart failure (Van Almen et al.,
2011).
With the development of the research
for roles of miRNAs in aging-related
heart failure, its cellular and molecular
mechanisms as well as pathophysiological
changes will be further clarified, which will
help develop novel miRNA-targeted ther-
apeutic strategies for heart failure in aged
people.
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